US 10526414
Use of anti-semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastases
granted A61KA61K2039/505A61K2039/507
Quick answer
US patent 10526414 (Use of anti-semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastases) held by VACCINEX, INC. expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- VACCINEX, INC.
- Grant date
- Tue Jan 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 6
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K2039/54, A61K2039/545